This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page
About Zinforo

About Zinforo

OverviewExtended spectrum coverageDosing

Dosing

Adult & adolescent dosingNeonatal & paediatric dosingEfficacy & Safety

Efficacy & Safety

EfficacyFOCUS Phase III Trial (CAP)CANVAS Phase III Trial (cSSTI)ASIA CAP Phase III TrialPaediatric EfficacyAdult safetyPaediatric SafetyClinical & Scientific Data

Clinical & Scientific Data

Patient Risk FactorsCAP patient profilescSSTI patient profilesCAPTURE studySupport & Resources

Support & Resources

Videos & case studiesVideos
Materials

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Discover more about the risk factors associated with disease severity, comorbidities and resistance in CAP and cSSTI

Risk of mortality in patients with infections increases with older age, the presence of comorbidities, disease severity and delayed initiation of appropriate antimicrobial therapy/ treatment failure5,7,12,17,19,23,28–31

Dr Matthew Dryden

In this short video recorded at EAHP in 2018, Matthew Dryden discusses key considerations in managing complex patients with cSSTI and CAP using two patient case studies. 

Initial treatment choice is key to success in patients with CAP or cSSTI, and initial treatment failure is more common in patients with comorbidities17Explore More Read several CAP patient profiles describing potential scenarios where Zinforo could be a treatment of choice. Access CAP patient profiles Loading Read several cSSTI patient profiles describing potential scenarios where Zinforo could be a treatment of choice.  Access cSSTI patient profiles Loading

Abbreviations

CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; cSSTI, complicated skin and soft tissue infections; CURB-65, Confusion, blood Urea, Respiratory rate, Blood pressure, age >65; ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus; PNSP, penicillin non-susceptible Streptococcus pneumoniae; PORT, Pneumonia Patient Outcomes Research Team; PVD, peripheral vascular disease.

Prescribing Information​​​​​​​

Zinforo® (ceftaroline fosamil)

Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion

Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion 

Dalacin C (clindamycin hydrochloride) 150mg capsules
Dalacin C (clindamycin hydrochloride) 75mg capsules
Dalacin C (clindamycin phosphate)  sterile solution for injection
Dalacin T (clindamycin phosphate) 1% topical lotion
Dalacin (clindamycin phosphate) 2% cream

References

ZINFORO. Summary of Product CharacteristicsHorita N, et al. Sci Rep 2015;5:14061Prina E, et al. Lancet 2015;386:1097–108Ramani A,  et al. J Chemother 2014;26:229–34Welte T, et al.Thorax 2012;67:71–9File TM, et al. Clin Infect Dis 2010;51:1395–405British Thoracic Society Community Acquired Pneumonia in Adults Guideline Group. Thorax 2009;64(SupplIII):iii1–iii55Eckmann C, et al. Eur J Med Res 2010;15:554–63Marwick C, et al. J Antimicrob Chemother 2011;66:387–97Cooke FJ, et al. Br Med Bull 2010;94:215–27Mannino DM, et al.Davis KJ, Kiri VA. Respir Med 2009;103:224–9Udeani G, et al. Hosp Prac 2014;42:109–15Luna CM, et al. Ann Am Thorac Soc 2016;13:1519–26Rajan S. Cleve ClinJ Med 2012;79:57–66Corey GR, et al. J Antimicrob Chemother 2010;65(Suppl4):iv41–iv51Amara S, et al. CurrMed Res Opin 2013;29:869–77Garau J, et al. Clin Microbiol Infect 2013;19:E377–E385Evans JD, et al. Postgrad Med 2014;126:128–34Dryden M, et al. Clin Microbiol Infect 2015;21:S27–S32Dryden M, et al. J Antimicrob Chemother 2016;71:3575–84Garcia-Vidal C, et al. Clin Microbiol Infect 2009;15:1033–8Alberti S, et al. Clin Infect Dis 2012;54:470–8Caballero J, et al. Ann Intensive Care 2011;1:48Dryden M, et al. J Antimicrob Chemother 2010;65(Suppl3):iii35–iii44Poulakou G, et al. Curr Opin Infect Dis 2017;30:158–71Mpenge MA, et al.Ther Clin Risk Manag 2015;11:565–79Augustine S, et al.Eur J Microbiol Immunol 2011;3:190–7Stupka J E, et al. Aging Health 2009;5:763–74Kothe H, et al. Eur Respir J 2008;32:139–46Garau J, et al. BMC Infect Dis 2015;15:78Edelsberg J, et al. Infect Control Hosp Epidemiol 2008;29:160–9
PP-ZFO-GBR-0230. September 2021
Tolerability profile of Zinforo

Access data on the tolerability profile of Zinforo as established in key Phase III cinical trials. 

 View tolerability profile  Loading CAPTURE study

To learn more about the efficacy of Zinforo in a real-world setting, explore the CAPTURE study.

 View CAPTURE study data Loading

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284 November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​